Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves’ Orbitopathy
source: Thyroid : Official Journal of the American Thyroid Association
authors: Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, Profilo MA, Mazzi B, Vitti P, Marcocci C, Brunetto M, Marinò Msummary/abstract:
High-dose intravenous glucocorticoid (ivGC) pulse therapy, which is commonly used for Graves’ orbitopathy (GO), has been associated with acute liver damage (ALD), resulting in a fatal outcome in a few cases. No certain risk factors for ALD have been established. Consequently, a large retrospective cohort study was performed.
The relationship between ALD and several potential risk factors was assessed in 1076 consecutive patients with GO given ivGC. ALD was defined as an increase of alanine aminotransferase >=300 IU/L.
Fourteen cases of ALD were recorded, resulting in a morbidity of 1.3%. Thirteen patients recovered and one died, resulting in a mortality of 0.09%. There was a significant, positive correlation of ALD with age and methylprednisolone acetate (MPA) cumulative dose, and ALD was more common (relative risk [RR]=2.8; p=0.05) in patients aged >=53 years (9/420; 2.14%) than in those aged <53 years (5/656; 0.76%). In patients aged >=53 years, there was a significant positive correlation of ALD with MPA cumulative dose, and with MPA dose per infusion. Thus, the frequency of ALD in this age group was greater (RR=3.48; p=0.04) in patients with a MPA dose per infusion >=0.7 g (5/111, 4.5% vs. 4/308, 1.29%). Regardless of age, no cases of ALD were observed for MPA doses per infusion <0.57 g.
Age and MPA dose are significant risk factors for ALD, with the following practical implications. First, the total MPA cumulative dose should not exceed 8.5 g (the average dose in patients without ALD). Second, in patients aged ≥53 years, selection and observation should be quite strict. However, being aged >=53 years should not be seen as an absolute contraindication to ivGC, especially in patients with severe GO, considering that the risk of ALD, although statistically significant, was relatively low. Third, the MPA dose should not exceed 0.57 g per infusion, a measure to be applied regardless of age.
Patients’ Expectations for the Functional and Psychosocial Outcomes of Orbital Decompression Surgery for Thyro...Patients with appearance-altering condit...
A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Grav...Context: Radioiodine is an effective an...
Maria Antonietta Altea, MDMaria Antonietta Altea, MD, is associate...
Type 2 Diabetic Patients With Graves’ Disease Have More Frequent and Severe Graves’ OrbitopathyBackground and Aims: Due to the worldwi...
Radioiodine-Associated Exacerbation of Graves’ Orbitopathy in the Japanese Population: Randomized Prospective ...Context: Exacerbation of Graves' orbito...
Efficacy of Orbital Radiotherapy in Moderate-to-Severe Active Graves’ Orbitopathy Including Long-Lasting Disease: ...Background: We aimed to explore the eff...
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Di...Graves’ disease is an autoimmune condi...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.